Table 6:
Association of treatment duration with treatment success
| Success (n) | Total (N) | Propensity score matched multivariate regression |
||||
|---|---|---|---|---|---|---|
| Pairs (n) | Adjusted OR (95% CI) | I2 | Adjusted RD (95% CI) | |||
| Duration of initial phase (months)* | ||||||
| 0·5−5·0 | 1169 | 1432 | ·· | 1 (ref) | ·· | ·· |
| 5·01−6·0 | 1381 | 1529 | 1529 | 1·7 (1·4−2·1) | NC | 0·06 (0·04 to 0·08) |
| 6·01−8·0 | 1602 | 1696 | 1695 | 3·2 (2·5−4·0) | NC | 0·09 (0·07 to 0·10) |
| 8·01−12·0 | 1346 | 1522 | 1519 | 1·4 (1·2−1·7) | NC | 0·05 (0·03 to 0·06) |
| 12·01−25·3 | 557 | 679 | 677 | 0·8 (0·7−1·0) | NC | −0·04 (−0·07 to −0·01) |
| Interval from culture conversion to end of initial phase (months)† | ||||||
| 0−1·0 | 239 | 251 | ·· | 1 (ref) | ·· | ·· |
| 1·01−3·0 | 668 | 695 | 694 | 1·5 (1·0−2·3) | NC | 0·02 (0·00 to 0·03) |
| 3·01−5·0 | 878 | 917 | 906 | 1·4 (1·0−2·0) | NC | 0·02 (0·00 to 0·03) |
| 5·01−7·0 | 1158 | 1179 | 1179 | 3·3 (2·1−5·2) | NC | 0·04 (0·03 to 0·05) |
| 7·01−15·0 | 1025 | 1080 | 1079 | 1·1 (0·8−1·5) | NC | 0·01 (−0·01 to 0·02) |
| Total duration of treatment (months)‡ | ||||||
| 6·0−11·9 | 119 | 176 | 174 | 0·6 (0·4−0·8) | 42·2% | −0·10 (−0·17 to −0·03) |
| 12·0−16·0 | 250 | 297 | ·· | 1 (ref) | ·· | ·· |
| 16·01−18·0 | 1349 | 1482 | 1482 | 2·8 (2·3−3·4) | 11·6% | 0·20 (0·18 to 0·22) |
| 18·01−20·0 | 1219 | 1264 | 1264 | 7·5 (5·5−10·1) | 10·6% | 0·23 (0·22 to 0·24) |
| 20·01−22·0 | 995 | 1091 | 1091 | 2·9 (2·3−3·6) | 11·1% | 0·19 (0·17 to 0·20) |
| 22·01−24·0 | 1609 | 1911 | 1911 | 1·5 (1·3−1·7) | 13·7% | 0·14 (0·12 to 0·17) |
| 24·01−36·9 | 1391 | 1611 | 1608 | 1·8 (1·5−2·0) | 17·7% | 0·16 (0·14 to 0·18) |
| Interval from sputum culture conversion to end of treatment (months)§ | ||||||
| 0·1−12·0 | 360 | 396 | 394 | 0·5 (0·4−0·7) | NC | −0·04 (−0·07 to −0·01) |
| 12·01−15·0 | 565 | 593 | ·· | 1 (ref) | ·· | ·· |
| 15·01−18·0 | 1206 | 1235 | 1223 | 2·1 (1·4−3·1) | NC | 0·02 (0·01 to 0·04) |
| 18·01−21·0 | 1122 | 1158 | 1154 | 1·6 (1·1−2·3) | NC | 0·02 (0·00 to 0·03) |
| 21·01−24·0 | 858 | 893 | 889 | 1·2 (0·9−1·8) | NC | 0·01 (−0·01 to 0·02) |
| 24·01−69 | 386 | 416 | 413 | 0·7 (0·4−1·0) | NC | −0·02 (−0·05 to 0·00) |
All duration analyses were restricted to the patients with treatment success or failure or relapse; the 3667 patients who died or were lost were excluded. Patients who were included or excluded in each analysis are detailed in the footnotes. OR=adjusted odds ratio. RD=adjusted risk difference. NC=not calculated.
6858 patients were included and 1505 patients were excluded (n=1323 not reported; n=182 initial phase > 25·3 months [>2 SDs from the mean]).
4122 patients included and 4241 excluded (n=3777 time to culture conversion or initial phase duration was not reported; n=390 conversion occurred after end of initial phase; n=74 sputum conversion occurred after 14·3 months [>2 SD]).
7832 patients included and 531 patients excluded (n=248 missing information; n=203 total duration <6 months; n=80 total duration >36·9 months [>2 SD]).
4691 patients included and 3672 excluded (n=3413 information about time to conversion or total duration missing; n=259 total duration <6 months, >36·9 months [>2 SD], or culture conversion was more than 14·3 months).